All lobbying filings

VIATRIS INC.

Lobbying for VIATRIS INC

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · Pennsylvania · House · Senate · $490,000.00 expenses · posted Apr 20, 2026

Official filing document

Bills named in this filing 9

S 891
Bipartisan Health Care Act
HR 1843
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
S 1302
Increasing Transparency in Generic Drug Applications Act
HR 4132
Prescription Information Modernization Act of 2025
S 2027
Prescription Information Modernization Act of 2025
S 2658
Medication Affordability and Patent Integrity Act
S 3778
Carbon Resource Innovation Act
S 3841
Last Sale Valuation Act of 2026
S 2296
National Defense Authorization Act for Fiscal Year 2026

Lobbying activity 5

Health Issues

S. 891, the Bipartisan Health Care Act Part D Formulary Design and Generic Drug Tiering H.R. 1843 / S. 1302 - Increasing Transparency in Generic Drug Applications Act HR 4132 / S.2027 - Prescription Information Modernization Act Medicaid Generics Penalty Implementation of the Inflation Reduction Act Drug Shortages S.2658 - The Medication Affordability and Patent Integrity Act

IP Issues related to generic medicines Patent Settlements S 1553, The PREVAIL Act

Trade (domestic/foreign)

Trade issues related to generic medicines Pharmaceutical supply chain S.3778: Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings Act S.3841: Last Sale Valuation Act

Financial Institutions/Investments/Securities

Policy related to corporate governance

Defense

S.2296 National Defense Authorization Act

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.